Volume | 40,647 |
|
|||||
News | - | ||||||
Day High | 0.4749 | Low High |
|||||
Day Low | 0.44 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Virios Therapeutics Inc | VIRI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.4609 | 0.44 | 0.4749 | 0.4695 | 0.4558 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
130 | 40,647 | US$ 0.4554253 | US$ 18,512 | - | 0.279 - 2.42 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:54:44 | formt | 450 | US$ 0.443 | USD |
Virios Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
9.05M | 19.26M | - | 0 | -5.3M | -0.28 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Virios Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VIRI Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.459 | 0.4749 | 0.401 | 0.4316864 | 94,282 | -0.016 | -3.49% |
1 Month | 0.4863 | 0.58 | 0.401 | 0.4952413 | 186,518 | -0.0433 | -8.90% |
3 Months | 0.42 | 0.6288 | 0.279 | 0.4327987 | 313,172 | 0.023 | 5.48% |
6 Months | 0.5141 | 1.04 | 0.279 | 0.5949792 | 396,011 | -0.0711 | -13.83% |
1 Year | 0.93 | 2.42 | 0.279 | 1.05 | 537,508 | -0.487 | -52.37% |
3 Years | 5.61 | 9.1109 | 0.218951 | 1.09 | 494,756 | -5.17 | -92.10% |
5 Years | 13.76 | 14.39 | 0.218951 | 1.57 | 474,679 | -13.32 | -96.78% |
Virios Therapeutics Description
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia. |